| Dr Pang Tsui, MD | |
|
1 Akron General Ave, Akron, OH 44307-2432 | |
| (330) 344-6000 | |
| Not Available |
| Full Name | Dr Pang Tsui |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 26 Years |
| Location | 1 Akron General Ave, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033114657 | NPI | - | NPPES |
| 2307766 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 35080775T (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Akron General Medical Center | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Partners Physician Group | 4183529340 | 488 |
News Archive
Some supposedly inert ingredients in common drugs - such as dyes and preservatives - may potentially be biologically active and could lead to unanticipated side effects, according to a preliminary new study by researchers from the UC San Francisco School of Pharmacy and the Novartis Institutes for BioMedical Research (NIBR).
Thirteen new PhD students are embarking on a research journey in the area of microwave imaging this month, as part of the EU project EMERALD - ElectroMagnetic imaging for a novel genERation of medicAL Devices.
For nearly nine years, researchers at Lund University have been working on developing implantable electrodes that can capture signals from single neurons in the brain over a long period of time - without causing brain tissue damage. They are now one big step closer to reaching this goal, and the results are published in the scientific journal Frontiers in Neuroscience.
Amid the coronavirus disease (COVID-19) pandemic, many theories have emerged about the disease and the treatments that can in supportive care. A recent theory emerged that suggests non-steroidal anti-inflammatory drugs (NSAIDs) might exacerbate the symptoms of the novel coronavirus. Now, a new study shows that there is no evidence for or against the use of NSAIDS, particularly ibuprofen, for patients with COVID-19.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013.
› Verified 7 days ago
| Entity Name | Partners Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841239274 PECOS PAC ID: 4183529340 Enrollment ID: O20031202000183 |
News Archive
Some supposedly inert ingredients in common drugs - such as dyes and preservatives - may potentially be biologically active and could lead to unanticipated side effects, according to a preliminary new study by researchers from the UC San Francisco School of Pharmacy and the Novartis Institutes for BioMedical Research (NIBR).
Thirteen new PhD students are embarking on a research journey in the area of microwave imaging this month, as part of the EU project EMERALD - ElectroMagnetic imaging for a novel genERation of medicAL Devices.
For nearly nine years, researchers at Lund University have been working on developing implantable electrodes that can capture signals from single neurons in the brain over a long period of time - without causing brain tissue damage. They are now one big step closer to reaching this goal, and the results are published in the scientific journal Frontiers in Neuroscience.
Amid the coronavirus disease (COVID-19) pandemic, many theories have emerged about the disease and the treatments that can in supportive care. A recent theory emerged that suggests non-steroidal anti-inflammatory drugs (NSAIDs) might exacerbate the symptoms of the novel coronavirus. Now, a new study shows that there is no evidence for or against the use of NSAIDS, particularly ibuprofen, for patients with COVID-19.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Pang Tsui, MD 224 W Exchange St Ste 220, Akron, OH 44302-1726 Ph: (330) 344-7040 | Dr Pang Tsui, MD 1 Akron General Ave, Akron, OH 44307-2432 Ph: (330) 344-6000 |
News Archive
Some supposedly inert ingredients in common drugs - such as dyes and preservatives - may potentially be biologically active and could lead to unanticipated side effects, according to a preliminary new study by researchers from the UC San Francisco School of Pharmacy and the Novartis Institutes for BioMedical Research (NIBR).
Thirteen new PhD students are embarking on a research journey in the area of microwave imaging this month, as part of the EU project EMERALD - ElectroMagnetic imaging for a novel genERation of medicAL Devices.
For nearly nine years, researchers at Lund University have been working on developing implantable electrodes that can capture signals from single neurons in the brain over a long period of time - without causing brain tissue damage. They are now one big step closer to reaching this goal, and the results are published in the scientific journal Frontiers in Neuroscience.
Amid the coronavirus disease (COVID-19) pandemic, many theories have emerged about the disease and the treatments that can in supportive care. A recent theory emerged that suggests non-steroidal anti-inflammatory drugs (NSAIDs) might exacerbate the symptoms of the novel coronavirus. Now, a new study shows that there is no evidence for or against the use of NSAIDS, particularly ibuprofen, for patients with COVID-19.
Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013.
› Verified 7 days ago
Daniel W Satariano, M. D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Dr. Edward S. Sunoo, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-8823 Fax: 330-296-6535 | |
Sheryl J Ontell-silverman, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 190 N Union St, Ste 104, Akron, OH 44304 Phone: 330-253-9145 Fax: 330-253-6222 | |
Dr. Laura Hays Ferguson, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-7040 Fax: 330-344-1714 | |
Dr. Tarun Bhalla, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-8823 Fax: 330-543-3593 | |
Grace Brown, CRNA Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-6000 |